AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2009, for Hemispherx Biopharma, Inc. The company is a specialty pharmaceutical firm focused on immune system-enhancing technologies. Its primary strategic focus is the clinical development of Ampligen (for Chronic Fatigue Syndrome and as a vaccine adjuvant) and the commercialization of Alferon N Injection (for genital warts). Commercial sales of Alferon N were halted in April 2008 due to inventory expiration, with production resumption targeted for late 2010 pending facility upgrades.

Key Financial Metrics

Note: The filing text does not provide explicit gross margin percentages; however, costs of goods sold ($146k for Q3) significantly exceed revenues ($25k for Q3).

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $6.1 million (Dec 31, 2008) to $61.0 million (Sep 30, 2009), driven by $61.8 million in financing proceeds.
• Revenue Decline: Nine-month revenues dropped from $240,000 in 2008 to $71,000 in 2009. This is primarily due to the cessation of Alferon N Injection sales in 2009, which contributed $173,000 in the prior year.
• Expense Reduction: General and Administrative (G&A) expenses decreased by 31% in Q3 and 22% for the nine months, attributed to a cash conservation program and reduced personnel costs.
• Share Count: Common shares outstanding increased from ~78.8 million to ~132.4 million due to private placements and warrant exercises.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Ampligen NDA: The FDA accepted the New Drug Application (NDA) for Ampligen in July 2008. The PDUFA action date was extended beyond May 25, 2009. The company is submitting additional reports in late 2009 regarding toxicology and manufacturing validation.
• Manufacturing: The Board approved up to $4.4 million for facility upgrades in New Brunswick, NJ, to prepare for FDA pre-approval inspections. Alferon N Injection could be available for commercial sale in late 2010.
• Financing: The company raised approximately $33.7 million in May 2009 via Rodman & Renshaw and utilized a $30 million standby agreement with Fusion Capital (maxed out at $28.1 million).

Risks and Contingencies:

• Regulatory Approval: No assurance that Ampligen will receive FDA approval. Delays or rejection would materially adversely affect operations.
• Product Liability: The company suspended product liability insurance for Ampligen and Alferon in November 2008, citing a lack of commercial sales and mandatory patient waivers. A claim could have a material adverse effect.
• Capital Needs: Future profitability is uncertain. The company may require additional financing, which could result in significant dilution. A proposal to increase authorized shares failed in September 2009, limiting immediate equity capacity.
• Legal Proceedings: Ongoing litigation includes a fraud suit against South African defendants (JCI, Kebble, Buidentag) and a dispute with Cato Capital LLC regarding placement fees.

Investor Verification Checklist

• FDA Status: Verify the current status of the Ampligen NDA review and any new FDA correspondence post-September 2009.
• Manufacturing Timeline: Confirm the progress of the $4.4 million facility upgrade and the feasibility of the late 2010 Alferon N Injection relaunch.
• Insurance Coverage: Assess the risk exposure resulting from the suspension of product liability insurance.
• Capital Structure: Review the impact of the failed vote to increase authorized shares on future fundraising capabilities.
• Legal Exposure: Monitor the outcome of the Cato Capital LLC lawsuit and the South African fraud litigation.